Introduction
Prostate cancer accounts for~15% of all malignancies worldwide and is the second most frequently diagnosed cancer amongst men [1, 2] . Widespread adoption of PSA screening has led to an increase in incidence over the last 25 years [3] . The effectiveness of several primary treatment options for prostate cancer has been established. Radical prostatectomy (RP) and radiotherapy (RT) are considered the main treatment options with curative intent [4] , other treatment options for patients with differing disease stages concern deferred treatment or hormonal therapy [5, 6] .
A previous Dutch study evaluated guideline adherence with national cancer registry data and found that about onequarter of all guideline users involved in prostate cancer care do not adhere to the Dutch guideline concerning recommendations on prostate cancer treatment [7] . As guidelines, both within and outside urology, often contradict each other and are of variable quality [8] [9] [10] [11] , and the optimum patient criteria for each primary treatment option remain unclear [12] , we aimed to systematically compare recommendations between international guidelines regarding the primary treatment modalities of prostate cancer to identify discrepancies and similarities.
Methods
We performed a Medline search on 12 May 2017, using a combination of free-text words and Medical Subject Headings (MeSH) terms for prostate cancer (Appendix I). We combined this with a validated search filter for guidelines and limited the search to guidelines published in the last 10 years [13] . We searched the National Guidelines Clearinghouse (https://www.guidelines.gov) and Guidelines
Results
A total of 375 references were retrieved from the search (Fig. 1 ). Of these, 34 overlapped between the different databases. In total, 33 articles were evaluated in the full-text screening. Of these, 11 were excluded because they did not provide any recommendations and eight were excluded because they did not concern any of the primary treatment options as a single treatment modality (i.e. combination of different treatments). The reasons for excluding articles in the full-text screening are provided in Appendix II. Finally, we included 14 guidelines from 12 unique organisations. A reference to the sources of data-retrieval for each recommendation in the corresponding included guidelines can be found in Appendix III.
American College of Radiology (ACR)
The two documents, with overlapping recommendations regarding brachytherapy, that are published by the ACR regarding brachytherapy and prostate cancer, both last revised in 2016, were included. Recommendations are based on the available literature and consensus [14, 15] .
AUA
The AUA guideline focuses specifically on localised prostate cancer and was last updated in 2017. The body of evidence, constructed by a systematic review, for particular treatments was assigned a strength rating (A-C) to support the recommendations. In the absence of sufficient evidence, additional information was provided as 'Clinical Principles' and 'Expert Opinions' [16] . 
Cancer Control Alberta
The guideline from Cancer Control Alberta addresses the complete pathway of patients with prostate cancer (including all stages) and was last revised in 2015. Recommendations are a consensus of the Alberta Provincial Genitourinary Tumour Team and are based on a systematic review of the literature [17] .
Cancer Council Australia
The identified guideline from Cancer Council Australia addressing localised prostate cancer (published in 2003) was rescinded by the National Health and Medical Research Council in 2013. Therefore, we did not incorporate this guideline in our analyses [18] .
EAU
The EAU guideline addresses the diagnosis, treatment, and follow-up of all stages of prostate cancer. The latest version was published in 2017. Recommendations were derived from a systematic review and are classified according to the level of evidence (I-IV) and graded A-C according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence [19] . All EAU guidelines will be adjusted in 2018, as another approach to grading the certainty of evidence will be used: the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [20, 21] .
European Society for Medical Oncology (ESMO)
The ESMO guideline regarding primary treatment of patients with prostate cancer (all stages included) was last revised in 2015. Expert authors have selected relevant literature. Levels of evidence (I-V) and grades of recommendation (A-E) have been adapted from the Infectious Disease Society of AmericaUnited States Public Health Service Grading System [22] . Statements without grading were considered justified standard clinical practice by the guideline authors and ESMO faculty [23] .
Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG)
The FROGG guideline concerning external beam radiotherapy (EBRT) for all patients with prostate cancer was published in 2010. A systematic review was conducted and each recommendation classified by a 'level of consensus' grade, adapted from the National Comprehensive Cancer Network (NCCN) categories of evidence and consensus [24] .
Belgian Health Care Knowledge Centre (KCE)
The guideline from the KCE concerns specifically the treatment of localised prostate cancer and the last version was published in 2013. The KCE adapted 20 international clinical guidelines regarding localised prostate cancer (e.g. AUA, EAU) to the Belgian healthcare context and updated the recommendations based on systematic reviews. A quality level of evidence (high, moderate, low, or very low) and grade of recommendation (strong or weak) were given to each recommendation using the GRADE methodology [21, 25] .
NCCN
The NCCN guideline addresses the diagnosis, treatment, and follow-up of all stages of prostate cancer. The latest version of the guideline was published in 2016 (third version). A systematic literature review was performed and recommendations were graded with the NCCN categories of Evidence and Consensus (Category 1-3). Recommendations without high-level evidence were mainly based on expert opinion [26] .
National Institute for Health and Care Excellence (NICE)
The guideline from NICE concerns the diagnosis and treatment of all stages of prostate cancer and was last revised in 2014. Recommendations are based on a systematic literature review. A qualifying statement, defining the nature of the evidence, follows each recommendation in accordance with the GRADE methodology [21, 27] .
Cancer Care Ontario's Programme in EvidenceBased Care (PEBC)
The guideline from PEBC regarding brachytherapy for patients with localised prostate cancer was published in 2012 in collaboration with the Genitourinary Cancer Disease Site Group. Evidence is based on a systematic literature review, without level of evidence or grading of recommendations [28] .
SIU
The guideline from SIU concerning the diagnosis, treatment, and follow-up of all stages of prostate cancer was published in 2011. The included evidence was obtained through a systematic review and is rated following a level of evidence scale (I-IV). The recommendations are graded (A-D) according to the Oxford Centre for Evidence-Based Medicine [29] .
definition of localised prostate cancer is different in the NCCN guideline, which states that any T-stage qualifies for localised prostate cancer, as long as there is no lymph node involvement (N0) or metastases (M0) [26] . Similarly, the guidelines of Cancer Control Alberta and the SIU define cT1-cT3, but not cT4 tumours as localised prostate cancer [17, 29] .
Risk-stratification schemes for localised prostate cancer are used as a tool to define the patient's prognosis and thereby provide recommendations concerning appropriate treatment modalities in all included guidelines. 
Primary Treatment
Active Surveillance
Active surveillance is advised in all guidelines for patients with low-risk prostate cancer ( [26] . In summary, differences in the recommendations regarding active surveillance are found in 
10-<20 In most guidelines, the highest T-stage used in the recommendations concerning active surveillance is cT2a, although any T2 tumour (including T2b and T2c) is accepted for active surveillance in the AUA, EAU, and ESMO guidelines (Table 2 ) [16, 20, 23] . In addition, some guidelines also take the life expectancy into account [16, 20, 26] . For calculating the life expectancy, several tools that can be used (e.g. the Social Security Administration tables and the WHO Life's Tables by country) are suggested in the guidelines. However, the preferred choice remains unclear [32, 33] .
Watchful Waiting
The terminology concerning 'watchful waiting' has been used heterogeneously in the included guidelines and terms such as conservative management or observation have also been used. However, the advised treatment is similar between the guidelines -monitoring of symptoms. Watchful waiting is generally recommended for patients with a shorter life expectancy, or those either unfit or unwilling to undergo active treatment modalities (Table 3 ) [16, 20, [23] [24] [25] [26] [27] 29] .
RP
In most guidelines, RP is recommended for patients with localised disease, with any PSA value, any Gleason score, and a life expectancy of >10 years (Table 4) [16, 17, 20, 26, 29] . The KCE guideline recommends RP for patients with a tumour stage <cT3, whilst the SIU guideline accepts ≤cT3, and the EAU, ESMO, and NCCN guidelines recommend RP for patients with any T-stage [20, 23, 25, 26] .
The AUA, EAU, and SIU guidelines give separate recommendations for nerve-sparing surgery, which is dependent on the tumour characteristics and sexual function (without further clarification) [16, 20, 29] . The EAU guideline specifically recommends nerve-sparing surgery for patients with a Gleason score ≤6, PSA level <10 ng/mL, and a T1c tumour [20] .
Lymph node dissection in combination with RP is mentioned in the guidelines of the AUA, Cancer Control Alberta, EAU, ESMO, NCCN, and SIU [16, 17, 20, 23, 26, 29] . The AUA, EAU, NCCN, and SIU guidelines specifically recommend extended lymph node dissection; however, other guidelines do not distinguish between various forms of lymph node dissections [16, 20, 26, 29] . The AUA, EAU and SIU guidelines recommend the extended lymph node dissection for patients with intermediate-or high-risk disease [16, 20, 29] . Using nomograms to predict the probability of finding positive lymph nodes for recommendations regarding a lymph node dissection are recommended by the guidelines of the EAU, NCCN and SIU [20, 26, 29] . The ESMO guideline recommends lymph node dissection for patients with high-risk and locally advanced prostate cancer [23] .
Brachytherapy
The guidelines of the ACR, AUA, Cancer Control Alberta, KCE, NCCN, and PEBC recommend low-dose-rate brachytherapy for both patients with localised low-risk disease and those with intermediate-risk disease [16, 23, [25] [26] [27] . However, in the EAU, NICE, and SIU guidelines low-dose-rate brachytherapy is recommended exclusively for low-risk patients (Table 5 ) [20, 27, 29] . Life expectancy is mentioned in some of the included guidelines for considering brachytherapy, with a threshold point of >10 years (Table 5 ) [15, 20, 26, 29] . 
No cores with >50% of core involvement
≤2 positive biopsies, core involvement ≤50% Age >70 years, only when healthy 
EBRT
The guidelines of the AUA, Cancer Control Alberta, EAU, ESMO, FROGG, KCE, NCCN, NICE and SIU recommend EBRT for patients with localised disease [16, 17, 20, [23] [24] [25] [26] [27] 29] . However, several differences regarding the PSA level (ranging from <10 to <20 ng/mL), Gleason score (ranging from ≤6 to ≤7), and T-stage (ranging from ≤T2a to ≤T2c) were found between the included guidelines (Table 6 ).
Hormonal Therapy
Hormonal therapy, defined as orchidectomy or a LHRH analogue/antagonist, is recommended for patients with advanced stages of prostate cancer in the guidelines of the AUA, Cancer Control Alberta, EAU, ESMO, NCCN, NICE, and SIU (Table 7) [16, 17, 20, 23, 26, 27, 29] . Additionally, hormonal therapy is recommended for patients who are either unfit or unwilling to receive local curative treatment [17, 20, 26, 29] .
Focal Therapy
Focal therapy, including cryotherapy and high-intensity focused ultrasound, is not recommended outside a clinical trial setting in the guidelines of the EAU, KCE, NCCN, NICE, and SIU [20, [25] [26] [27] 29] . The guideline of Cancer Control Alberta from 2015 recommends cryotherapy to patients with localised high-risk disease, defined as patients with a cT3 stage, PSA level >20 ng/mL, or Gleason score ≥8 [17] . Whole gland cryosurgery is recommended in the AUA guideline for patients with a tumour stage <cT3, PSA level <20 ng/mL, and Gleason score ≤7 [16] . Table 3 The recommendations regarding watchful waiting in the included guidelines stratified by TNM stage, life expectancy, patient preferences, and other variables.
Guideline
Watchful waiting recommendations cT cN cM Life expectancy, years Patient preferences Extra Comorbidities Extra
540
© 2018 The Authors BJU International © 2018 BJU International Table 6 The recommendations regarding EBRT in the included guidelines stratified by PSA level, Gleason score, and TNM stage.
Guideline EBRT recommendations
PSA, ng/mL Gleason score cT cN cM 
Discussion
Based on our systematic review, including 14 guidelines from 12 international organisations, we conclude that considerable discrepancies between the guidelines' recommendations regarding primary treatment of prostate cancer exist. The largest differences are found in recommendations for active surveillance, brachytherapy, and EBRT. The differences in treatment recommendations are mainly caused by inconsistencies regarding the patients' characteristics, including TNM stage, PSA level, and Gleason score, in the risk stratification [34] . Differences in risk stratification might be partly attributed to the inconsistent use of imaging in the diagnosis of prostate cancer [35] .
Guidelines regarding the treatment of localised prostate cancer from different organisations vary in methodological quality, ranging from consensus-based guidance to recommendations based on systematic review of the available literature. Additionally, the quality of the guidelines regarding prostate cancer was found to be suboptimal [11] . Different methods of various quality and reproducibility were used to score the levels/quality of evidence of the recommendations. Future guidelines would benefit from using a systematic and explicit approach, such as GRADE, to making judgements about quality of evidence and strength of recommendations [21] . A study comparing international guidelines regarding recommendations concerning active surveillance for prostate cancer, found a similar variety in used criteria, indicating a lack of consensus on optimal intervention thresholds [10] . The inconsistencies in recommendations might also be partly attributed to the time of publication. The time of publication of the included guidelines ranged from 2010 (FROGG) to 2017 (AUA and EAU) [16, 20, 23] .
It is likely that the reported discrepancies in recommendations will lead to international variation in clinical practice concerning the treatment of patients with prostate cancer. The proportion of patients with localised prostate cancer with RP ranges from 15% to 50% internationally. For RT the variation is similar; 30-60% of the men received RT [36] [37] [38] [39] . Worldwide, even a larger variation is seen in the use of active surveillance in patients with lowrisk disease; ranging from 10% to 29% in the USA to 74% in Sweden [36, [38] [39] [40] [41] [42] . Patient preferences play a large role in deciding which primary treatment modality will be used and, preferably, all clinical guidelines should be developed taking patients' preferences into account. [43, 44] .
Finally, the patients' age also plays a role in the choice of therapy; with increasing age the proportion of patients treated surgically decreases whereas the proportion of patients with RT increases [39] . To prevent both overtreatment and undertreatment in elderly patients with prostate cancer, biological age seems an inadequate variable for deciding on primary treatment options in prostate cancer [2, 45] . Preferably, life expectancy should be taken into account in guidelines' recommendations [46] . However, life expectancy is often neglected in the included guidelines and a preferred tool for calculating patients' life expectancy remains unclear.
Several limitations should be taken into account when interpreting the results of our present review. First, it is possible that due to suboptimal indexing of guidelines not all guidelines meeting our inclusion criteria have been identified and other clinical guidelines regarding the treatment of prostate cancer might exist (and used regionally or in specific hospitals) and are missed in our review. Additionally, due to limitations in the reporting of the methods of the guidelines, we were not able to provide information as to whether the individual recommendations of the guidelines were based on systematic reviews or narrative reviews/consensus.
Key Points
• One of the main discrepancies between guidelines regarding the primary treatment of prostate cancer is the definition of localised prostate cancer.
• Different threshold values for the TNM stage, PSA values, and Gleason scores were used amongst the guidelines to determine the different risk groups.
• Recommendations regarding active surveillance, brachytherapy, and EBRT vary between the included international guidelines.
• RP is consistently advised for those with localised prostate cancer and a life expectancy of >10 years. However, the preferred tool for calculating life expectancy remains unclear.
• Recommendations regarding RP and hormonal therapy as monotherapy are largely homogeneous in the included international guidelines.
• Focal therapy is not recommended outside a clinical trial setting.
• Differences in recommendations might be caused by year of publication and the varying methodological quality of guidelines. 
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